EyePoint Starts Global Phase 3 Trials for DURAVYU

EyePoint Pharmaceuticals ( (EYPT) ) just unveiled an update.

On March 2, 2026, EyePoint announced that the first patients have been dosed in its global Phase 3 COMO and CAPRI clinical trials evaluating DURAVYU for diabetic macular edema, signaling the start of pivotal late-stage testing in a major retinal indication. These randomized, aflibercept-controlled non-inferiority studies, each targeting about 240 patients and using six‑month redosing, are designed to leverage positive Phase 2 VERONA data and prior regulatory alignment in the U.S. and Europe to demonstrate that DURAVYU can match standard-of-care vision outcomes while reducing treatment burden.

The launch of these DME trials, alongside an already fully enrolled Phase 3 program in wet AMD, underscores EyePoint’s bid to establish DURAVYU as a first- and best-in-class sustained-release tyrosine kinase inhibitor in the two largest retinal disease markets. Successful results, with topline DME data expected in the second half of 2027 and wet AMD data anticipated beginning in mid-2026, could materially strengthen the company’s competitive position in ophthalmology, offering patients a longer-acting, multi-mechanism alternative to existing anti-VEGF therapies and potentially reshaping treatment paradigms for vision‑threatening diabetic eye disease.

The most recent analyst rating on (EYPT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

Spark’s Take on EYPT Stock

According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.

EyePoint Pharmaceuticals’ overall stock score reflects significant financial challenges, including declining revenues and persistent losses. However, strong technical momentum and positive corporate developments, such as successful trial updates and fundraising, provide a counterbalance. The company’s strategic focus on innovative treatments and clinical progress offers potential for future growth, despite current valuation challenges.

To see Spark’s full report on EYPT stock, click here.

More about EyePoint Pharmaceuticals

EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative sustained-delivery therapeutics for serious retinal diseases. Its lead product candidate, DURAVYU, combines the tyrosine kinase inhibitor vorolanib with the company’s proprietary bioerodible Durasert E intravitreal delivery technology and is being advanced in Phase 3 pivotal trials for wet age-related macular degeneration and diabetic macular edema, supported by prior safety and efficacy data across multiple clinical studies.

Headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts, EyePoint targets large, multi-billion-dollar retinal disease markets and has a legacy of four approved ophthalmic drugs over three decades, with tens of thousands of eyes treated using its technologies. The company holds an exclusive license to vorolanib for localized ophthalmic use outside China, Macao, Hong Kong and Taiwan, and positions itself as a partner to the retina community while seeking to build long-term shareholder value.

Average Trading Volume: 1,351,538

Technical Sentiment Signal: Buy

Current Market Cap: $1.45B

Learn more about EYPT stock on TipRanks’ Stock Analysis page.